The CRISPR Cas patent files, part 4: All back to zero, think again!
Journal of biotechnology, 407: 78-86 PMID 40854411 DOI 10.1016/j.jbiotec.2025.08.001
Abstract
The epic patent disputes regarding CRISPR Cas9 have been keeping the Biotech community abuzz over the last 10 years. The unclear situation has created, and keeps creating, serious uncertainties among users of this groundbreaking technology. This article gives an overview of the dispute's history, and explains the actual state of the debate.